Literature DB >> 29532523

Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.

Takuya Furuta1, Hiroaki Miyoshi1, Satoru Komaki1,2, Fumiko Arakawa1, Motohiro Morioka2, Koichi Ohshima1, Mitsutoshi Nakada3, Yasuo Sugita1.   

Abstract

Epithelioid glioblastoma (eGBM) is a rare variant of GBM which was adopted in the 2016 WHO classification. eGBM and pleomorphic xanthoastrocytoma (PXA) sometimes show overlapping features histologically and genetically, such as epithelioid pattern and a highly frequent V600E mutation in the gene for vRAF murine sarcoma viral oncogene homolog B1 (BRAF), respectively. Accurate diagnosis of these rare tumors is challenging according to the new criteria in the revised 2016 WHO classification. It is an urgent task to elucidate the biological properties of the tumors and to select appropriate treatment. Twenty consecutive cases diagnosed as PXA or eGBM histologically were investigated. Twelve of the 20 cases were PXAs and eight were eGBMs. Morphologically, mitotic activity, necrosis and degenerative changes such as intracellular lipid accumulation, eosinophilic granular bodies and reticulin fiber deposits were scored. Immunohistochemical and molecular biological assessment for isocitrate dehydrogenases 1 and 2 (IDH1/2), α-thalassemia/mental-retardation-syndrome-X-linked gene (ATRX), p53, BRAF, telomere reverse transcriptase promoter (TERT-p), H3F3A, and integrase interactor 1 (INI1) were performed. eGBM tended to lack the degenerative changes characteristic for PXA. Of the 20 cases tested, Sanger technique showed no mutation in IDH1/2. BRAF mutation at T1799 > A (V600E) was detected in 4/12 (33.3%) PXA and 4/8 (50.0%) eGBM, while TERT-p mutation was detected at C228 > T in 2/12 (16.7%) PXA and at C250 > T in 1/8 (12.5%) eGBM. Retained nuclear ATRX was observed in 12/12 (100%) PXA and 6/7 (85.7%) eGBM while p53 mutation was observed in 2/10 (20%) PXA and 7/7 (100%) eGBM. All tumors retained INI1 expression in their nuclei. None of the tumors harbored H3F3A mutation. One PXA without BRAF mutation acquired TERT-p mutation at recurrence and one eGBM harbored both BRAF and TERT-p mutation. Molecular biological similarity between eGBM and PXA was suggested in our series, while degenerative changes reflected the features of PXA. It was speculated that the common genetic alterations for development and progression of eGBM and PXA might include BRAF and TERT-p mutations.
© 2018 Japanese Society of Neuropathology.

Entities:  

Keywords:  biomarker; epithelioid glioblastoma; integrated diagnosis; pleomorphic xanthoastrocytoma

Mesh:

Substances:

Year:  2018        PMID: 29532523     DOI: 10.1111/neup.12459

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  8 in total

1.  Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.

Authors:  Kaijun Sun; Xingwang Zhou; Tengfei Li; Mingrong Zuo; Junhong Li; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2021-02-17       Impact factor: 3.042

Review 2.  The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.

Authors:  Swati Mahajan; Iman Dandapath; Ajay Garg; Mehar C Sharma; Vaishali Suri; Chitra Sarkar
Journal:  Lab Invest       Date:  2022-01-14       Impact factor: 5.662

Review 3.  Oncogenic BRAF Alterations and Their Role in Brain Tumors.

Authors:  Felix Behling; Jens Schittenhelm
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

4.  Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review.

Authors:  Ying Zeng; Xiangfeng Zhu; Yali Wang; Bo Liu; Xin Yang; Qiushi Wang; Juan Du; Yu Ma; Li Lin; Ping Fu; Hualiang Xiao; Qiao-Nan Guo
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

Review 5.  Pediatric low-grade glioma in the era of molecular diagnostics.

Authors:  Scott Ryall; Uri Tabori; Cynthia Hawkins
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

6.  Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.

Authors:  Azadeh Ebrahimi; Andrey Korshunov; Guido Reifenberger; David Capper; Joerg Felsberg; Elena Trisolini; Bianca Pollo; Chiara Calatozzolo; Marco Prinz; Ori Staszewski; Leonille Schweizer; Jens Schittenhelm; Patrick N Harter; Werner Paulus; Christian Thomas; Patricia Kohlhof-Meinecke; Marcel Seiz-Rosenhagen; Till Milde; Belén M Casalini; Abigail Suwala; Annika K Wefers; Annekathrin Reinhardt; Philipp Sievers; Christof M Kramm; Nima Etminam; Andreas Unterberg; Wolfgang Wick; Christel Herold-Mende; Dominik Sturm; Stefan M Pfister; Martin Sill; David T W Jones; Daniel Schrimpf; David E Reuss; Ken Aldape; Zied Abdullaev; Felix Sahm; Andreas von Deimling; Damian Stichel
Journal:  Acta Neuropathol Commun       Date:  2022-01-10       Impact factor: 7.801

7.  Malignant transformation of pleomorphic xanthoastrocytoma in pregnant patient: Clinical case and ethical dilemma.

Authors:  Jurica Marakovic; Darko Chudy; Danko Muller; Damir Tomac; Petar Marcinkovic; Darko Oreskovic; Andjelo Kastelancic; Marina Raguz
Journal:  Surg Neurol Int       Date:  2021-09-20

8.  Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.

Authors:  Lily J Andrews; Zak A Thornton; Saanwalshah S Saincher; Ian Y Yao; Sarah Dawson; Luke A McGuinness; Hayley E Jones; Sarah Jefferies; Susan C Short; Hung-Yuan Cheng; Alexandra McAleenan; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 12.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.